» Articles » PMID: 14977598

Tumor-suppressive and Promoting Function of Transforming Growth Factor Beta

Overview
Journal Front Biosci
Specialty Biology
Date 2004 Feb 24
PMID 14977598
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Transforming growth factor beta (TGFbeta) is a multifunctional polypeptide. Its role in carcinogenesis can be either suppressive or promoting depending on tumor developmental stages and cellular context. During the early phase of epithelial tumorigenesis, TGFbeta inhibits primary tumor development and growth by inducing cell cycle arrest and possibly apoptosis. However, in late stages of progression, as tumor cells evade the growth inhibition by TGFbeta due to inactivation of its signaling pathway or aberrant regulation of cell cycle machinery, the role of TGFbeta signaling is often switched from tumor suppression to promotion. TGFbeta can apparently act in tumor stroma as well as tumor cells to inhibit host immune surveillance and stimulate invasion, angiogenesis, and metastasis. Studies have shown that antagonizing TGFbeta activity can inhibit tumor progression, especially metastasis, in certain tumor models. However, the molecular markers that can indicate the feasibility of the use of TGFbeta antagonists as cancer therapeutics remain to be determined.

Citing Articles

Geniposide Inhibits Non-Small Cell Lung Cancer by Regulating Proliferation, Apoptosis, Invasion, Migration, Epithelial-Mesenchymal Transition, and Cancer Stem-Like Cell Property Via Wnt/β-Catenin Pathway.

He H, Li Y, Wang Y, Li M Biochem Genet. 2025; .

PMID: 39964646 DOI: 10.1007/s10528-025-11030-5.


Down-regulation of HOXB5 inhibits TGF-β-induced migration and invasion in hepatocellular carcinoma cells inactivation of the PI3K/Akt pathway.

Sun J, Ge Q, Ren Z, Sun X, Xie S RSC Adv. 2022; 8(72):41415-41421.

PMID: 35559288 PMC: 9091567. DOI: 10.1039/c8ra06860g.


Reciprocal crosstalk between endometrial carcinoma and mesenchymal stem cells via transforming growth factor-β/transforming growth factor receptor and C-X-C motif chemokine ligand 12/C-X-C chemokine receptor type 4 aggravates malignant phenotypes.

Ding D, Chu T, Liu H Oncotarget. 2018; 8(70):115202-115214.

PMID: 29383153 PMC: 5777765. DOI: 10.18632/oncotarget.23212.


A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer.

Cohn A, Lahn M, Williams K, Cleverly A, Pitou C, Kadam S Int J Oncol. 2014; 45(6):2221-31.

PMID: 25270361 PMC: 4215585. DOI: 10.3892/ijo.2014.2679.


Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model.

Biswas T, Gu X, Yang J, Ellies L, Sun L Cancer Lett. 2013; 346(1):129-38.

PMID: 24368187 PMC: 3947668. DOI: 10.1016/j.canlet.2013.12.018.